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Abstract
Background: A prospective multicenter clinical study was performed to evaluate the safety and efficacy of a
bovine dermal graft (Xenform® Matrix, Boston Scientific, Natick, MA, USA) during vaginal reconstructive surgery.
Methods: Forty-five women with ICS stage 2 or higher pelvic organ prolapse (POP) were enrolled at 4 centers.
POP-Q, pelvic floor function (PFDI-20), sexual function (PISQ-12), and patient satisfaction tools were used to assess
subjects at baseline, and at 2 and 6 weeks, and 3, 6 and 12 months post surgery. The significance of symptom
score changes at 6 months and 1 year were determined by the t-test for paired data. Forty-three of the 45 patients
completed the 12 month study.
Results: The majority of the subjects had cystocele (98%) and/or rectocele (84%) defects at study entry. At 12
months, 74% of the defects had improved to a stage 0 or 1. Mean PFDI-20 scores improved by 72% (p < 0.001) at
12 months, and PISQ-12 scores were maintained during the follow-up period indicating no decline in sexual
function. Three subjects experienced one serious adverse event each; one of the adverse events (constipation) was
deemed by the study physician to be unrelated to Xenform®. One subject had severe pyelonephritis resulting in
dialysis. This subject had a previous history of pyelonephritis, sepsis and acute renal failure. The third subject had a
reported recurrent cystocele of moderate severity, possibly related to the device. No graft related erosions or pain
lasting more than 30 days were reported. No subjects withdrew due to an adverse event.
Conclusion: This study is the first to investigate the use of Xenform® Matrix in vaginal reconstructive surgery
among patients with POP. Significant improvement was maintained at 12 months utilizing both objective and
subjective assessment tools, confirming the safety and efficacy of this material in vaginal surgery.
Trial Registration: ClinicalTrials.gov NCT01244165
Background
Women face an 11% lifetime risk of requiring major
surgery for pelvic organ prolapse (POP) [1]. Among the
goals of pelvic reconstructive surgery for POP are relief
of symptoms, restoration of normal anatomy, mainte-
nance of vaginal capacity for sexual function, and
improvement in quality of life. Even though the surgical
techniques for repair of POP continue to be refined and
improved, the re-operation rate for persistent or recur-
rent prolapse is relatively high [2]. In an effort to improve
long term success rates of POP surgery, surgeons have
incorporated various synthetic or biological prosthetic
materials in pelvic reconstructive procedures, as is also
done in abdominal wall hernia repair.
Graft materials have long been used as adjuncts, with
excellent efficacy and safety, and their use may be
extended into anterior and posterior vaginal repairs. In
this way, grafts are being used to reinforce repairs, or to
r e p l a c et h es u p p o r t i v et i s s u et h a ti se i t h e rd e f i c i e n to r
absent [3]. Depending on their placement, grafts can
correct both central and lateral anterior vaginal wall
defects, as well as those involving the rectovaginal
septum. * Correspondence: hgoldstein@christianacare.org
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available synthetic patches. These include the capability
for in-vivo tissue remodeling and consequent reduction
in the rates of extrusion and/or erosion [4]. Limitations
include the inherent biological variability of tissue, cost
of the material, size constraints related to harvest sites,
and lack of long term data [4]. The types of biological
grafts used in pelvic reconstructive surgery have
included autografts, allografts, and xenografts [5]. Of
these, acellular xenografts are attractive because they are
readily available with more uniform thickness, and exhi-
bit good biocompatibility. Xenform® Matrix (Boston
Scientific Corp., Natick, Massachusetts, USA), is an acel-
lular noncrosslinked collagen-based xenograft derived
from fetal bovine dermis, and is designed to provide a
sturdy molecular scaffold that is gradually reabsorbed
and replaced by native connective tissue. Xenogenic col-
lagen-based graft substitutes have become increasingly
popular for dural repair, where a canine duraplasty
model has confirmed collagen remodeling with the Dur-
epair® fiber network (Medtronic, St Paul, Minnesota,
USA) becoming increasingly populated by fibroblast and
a supporting vasculature at 1, 3 and 6 months [6].
The objective of this multicenter trial was to evaluate
the safety and effectiveness of Xenform Matrix with
respect to restoration of normal anatomy, symptom
relief, quality of life, and sexual function over a 1 year
period.
Methods
A prospective cohort of women who received Xenform
Matrix during pelvic reconstructive surgery at four US
centers from June 2004 to October 2005 was studied.
Prior to initiating this trial all four centers received
approval from the Institutional Review Boards at their
institutions. This trial was conducted in accordance with
the principles espoused by the Declaration of Helsinki
and all local regulations. All patients provided written
informed consent. Xenform Soft Tissue Repair Matrix
was developed and manufactured for this study by TEI
Biosciences Inc. (Boston, Massachusetts, USA), and was
referred to as Cytrix™ in this multicenter clinical trial;
this material is now referred to as Xenform® Matrix–a
registered trademark of Boston Scientific Corporation
(Natick, Massachusetts, USA).
Eligibility
Women over 18 years of age with International Conti-
nence Society (ICS) stage 2 or greater POP were eligible
for study entry. Exclusion criteria consisted of dermal
graft implantation during prior pelvic surgery; diabetes
mellitus; morbid obesity; a pelvic mass; unexplained
abnormal vaginal bleeding; infection; coagulopathy; par-
ticipation in another investigational device or drug
study; pregnancy; life expectancy <2 years; hypersensitiv-
ity to collagen or bovine materials; history of soft tissue
pathology at the intended implant site; impaired wound
healing; and any autoimmune connective tissue disease.
Endpoints
All subjects entered into the study were examined or
interviewed over the phone at 2 weeks, 6 weeks, 3 months,
6 months, and 1 year after their surgery. Postoperative
symptomatic relief was assessed through the use of a stan-
dardized validated instrument: the Pelvic Floor Distress
Inventory (PFDI-20) [7]. Postoperative sexual function was
assessed through the use of a standardized validated
instrument: the Pelvic Organ Prolapse Sexual Question-
naire (PISQ-12) [8]. The PFDI-20 is a psychometrically
validated, condition specific questionnaire consisting of
three scales addressing POP distress, colorectal and anal
distress, and urinary distress. The PFDI-20 has been
shown to be reliable and responsive in a comprehensive
assessment of the effect of pelvic floor disorders on quality
of life [7]. The PISQ-12, developed specifically to evaluate
sexual function in women with POP and/or urinary incon-
tinence, has been validated and shown to exhibit moderate
to high reliability [8]. Anatomical success was defined as
an improvement of greater than 1 ICS stage in POP com-
pared to baseline. Pelvic organ prolapse quantification
(POP-Q) is a standardized, validated system for defining
the extent of the prolapse. The POP-Q points are con-
verted to a staging system developed by the ICS [9]. The
primary endpoint was clinical data at 6 months, assessed
by the PFDI-SF20 Questionnaires, PISQ-12 Question-
naires, Patient-Phone Questionnaires, and Physician Satis-
faction Questionnaires, in addition to analysis of the
collected clinical data. Secondary end points were clinical
data, PFDI-SF20 Questionnaires, and PISQ-12 Question-
naires at 12 months of follow-up.
Xenform Matrix Placement
Xenform Matrix was soaked in sterile, room tempera-
ture 0.9% saline for approximately one minute, based on
previously studied tissue characteristics, to accomplish
the recommended hydration. The protocol intentionally
did not define a specific procedure to determine the size
or shape of the implant. The study was instead designed
to test this material as used by different surgeons using
their individual techniques. The supplied 8 cm × 12 cm
sheet of Xenform Matrix was trimmed to the desired
size and shape either before or after the hydration pro-
cess, as determined by the surgeon. The graft was
immersed in sterile saline until ready for use and was
then sutured in place using standard suturing techni-
ques with bites in the graft material and host tissue.
Typically, sutures were first anchored to the ligament of
interest under direct visualization, and then attached to
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nique and suture material used was determined by the
individual surgeon.
Subject Evaluation
During the baseline subject evaluation a medical history
was taken, and physical and pelvic examinations per-
formed. Follow-up evaluations were performed at
2 weeks, 6 weeks, 3 months, 6 months, and 1 year after
surgery. The subjects completed at baseline and at each
follow-up visit the PFDI-20 and PISQ-12 questionnaires.
The occurrence of intra-operative complications and
postoperative adverse events was documented.
Statistical Analysis
Descriptive statistics for continuous variables consisted
of the mean and standard deviation (SD). The signifi-
cance of symptom score changes at 6 months and
1 year were determined by the t-test for paired data.
The rate of clinical success was calculated as the percen-
tage of subjects showing improvement from baseline of
at least one prolapse stage. Exact binomial 95% confi-
dence intervals (CI) around point estimate of success
rate were also computed. Between group difference in
success rate was evaluated with the Fisher exact test. All
statistical analyses were performed using SAS for
Windows version 8.2 or higher (SAS institute Inc., Cary,
North Carolina, USA).
Results
Forty-six subjects were enrolled in the study. Forty-five
subjects underwent pelvic floor reconstruction with the
Xenform Matrix. Forty-three subjects completed the
study. Of the 3 subjects who did not complete the
study, one withdrew her consent after screening but
before her surgery and the other two dropped out
3 months and 6 months after their surgery.
The demographics of the subjects are presented in
Table 1. Twenty-three subjects (51%) had a prior hyster-
ectomy, 18 percent had a prior anterior wall repair, 2%
had a prior vault suspension, and 13% had a prior pos-
terior wall repair. The most common presenting defect
was a cystocele (98%), but 84% also had a rectocele.
Fourteen subjects (31%) underwent a concomitant hys-
terectomy at the time of her prolapse repair. Forty-three
subjects (96%) underwent general anesthesia during
their reconstruction and the other 2 (4%) had spinal
anesthesia. The average procedure time was 153 minutes
(SD 53.0). The average length of stay for the subjects
was 1.8 days (SD 0.5).
The anatomical outcomes are listed in Table 2. The
improvement from surgery was evident at the primary
endpoint of 6 months, which persisted at the 1 year fol-
low-up. At 1 year, 88% of subjects had a successful out-
come based upon improvement of their ICS stage. The
mean Point Ba on the POP-Q exam was +1.7 cm at
baseline and improved to -1.7 cm at 1 year. The mean
Point Bp on the POP-Q exam was -0.2 at baseline and
improved to -2.5 cm at 1 year. These findings are statis-
tically significant. The total vaginal length did not
change from the surgery, however the vaginal apical
support (point C) significantly improved by 130% after
surgery (from -3.0 to -6.9 cm). There was no statistically
significant change from the 6 month follow-up to the
1 year follow-up (Ba, C and TVL), however, the change
for Bp was significant (P = 0.002 for the change between
6 months and 1 year). Mean PFDI-20 scores improved
by greater than 70% (P <0 . 0 0 1 )a t6m o n t h sa n dt h i s
improvement remained the same at 1 year (Table 3).
The PISQ-12 scores improved from baseline (P = 0.023)
at 6 months and then were maintained at the 1 year
exam (Table 4). Two patients reported dyspareunia,
unrelated to the graft.
Three subjects experienced one serious adverse event
each; one of the adverse events (constipation) was
deemed by the study physician to be unrelated to Xen-
form. One subject had severe pyelonephritis resulting
in dialysis. This subject had a previous history of pye-
lonephritis, sepsis, and acute renal failure. The third
subject had a reported recurrent cystocele of moderate
severity, possibly related to the device. No graft related
erosions or pain lasting more than 30 days were
reported. No subjects withdrew due to an adverse
event.
Table 1 Demographics and Baseline Characteristics
Mean (SD)
Age 60.2 (11.8)
BMI 28.7 (5.5)
Parity 2.9 (1.1)
N (%)
On Estrogen Replacement 14 (31.1)
Post Menopausal 37 (82.2)
Prior Hysterectomy 23 (51.1)
Prior Prolapse Surgery 16 (35.5)
Table 2 Anatomical Outcomes
POP-Q
Points
Baseline
(cm)
6 Months
(cm)
1 Year
(cm)
P
value*
Ba 1.7 -1.9 -1.7 <0.001
Bp -0.2 -2.8 -2.5 <.0001
C -3.0 -7.0 -6.9 <.0001
TVL 8.9 8.4 8.7 NS
NS: not statistically significant; POP-Q: Pelvic Organ Prolapse Quantification
System
*compared to baseline exam
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This multicenter study is the first to investigate the use
of Xenform® Matrix in pelvic floor reconstruction
a m o n gs u b j e c t sw i t hP O P .T h i ss t u d ys h o w st h a ta t
1 year subjects who underwent pelvic reconstruction
using this acellular noncrosslinked xenograft derived
from fetal bovine dermis had statistically significant
improvement in both subjective and objective measure-
ments. There were no erosions noted with this material
and it appeared to be safe and efficacious in the treat-
ment of POP.
The current study demonstrated an 88% success rate
(defined as ICS stage improvement relative to baseline),
with mean Ba and Bp points on the POP-Q exam of
-1.7 cm and -2.5 cm, respectively, at 1 year and PFDI-20
and PISQ-12 scores of 34.0 ± 31.7 and 34.7 ± 5.9,
respectively. By comparison, a study of a bovine pericar-
dium collagen matrix implant demonstrated a success
rate (defined as Ba of more than -1) of 85.7% at 1 year
[10]. In a study of a porcine xenograft matrix (Pelvicol,
CR Bard, Covington, GA, USA), the surgical success
rate was 94%, defined as grade 0 or grade 1 [11]. Paraiso
et al. 2006 [12] studied a porcine small intestine submu-
cosa graft in 32 patients and found a success rate of
54% (defined as Bp ≤ -2) at 1 year with a PFDI-20 score
o f3 4±3 7( n=2 4 )a n daP I S Q - 1 2s c o r eo f3 3±8 .A n
extensive analysis of comparative studies assessing syn-
thetic and biologic graft use for the treatment of ante-
rior and posterior POP has also been conducted by the
Society of Gynecologic Surgeons [13,14], including sev-
eral studies of porcine dermal grafts (Pelvicol) reporting
failure rates of 7-36%, depending on definition, at 12-15
months post-surgery [15-18] and Vicryl mesh synthetic
grafts (Ethicon, Somerville, NJ, USA) reporting failure
rates of 0-36% at 12-15 months [17,19].
The study protocol did not mandate a particular pro-
cedure for placement of the graft material, in order to
allow the material to be studied in a variety of ways at
the discretion of the individual surgeon. If a particular
surgical technique or graft size had been mandated, the
results could only be applied under those conditions,
rather than across the broad variety of techniques. To
date, no one particular technique or graft size has been
shown to be the ideal procedure. In this study, the four
separate clinical settings were able to customize the
graft to individual preference with favorable subjective
and anatomical findings.
One unexpected outcome from this study was the
finding that the results at 6 months were almost identi-
cal to the 1 year outcomes (both success and failures).
This finding demonstrates that in this trial the 6 month
data points acted as a direct correlation to the 1 year
data points. If a subject with the Xenform Matrix has
success (both objective and subjective) at 6 months post
surgery then one may expect these same results to hold
at 1 year. This also was found in subjects having no
relief at 6 months. If this finding holds true for other
research in pelvic floor reconstruction graft materials
then it can perhaps help design further trials with these
materials. If researchers knew that 6 months in pelvic
floor research results were equivalent to 1 year results,
then trials might be designed in a more efficient man-
ner. But it is not clear whether the 6-month findings
would be stable with other (particularly non-xenograft)
materials or other non-tested surgical repair techniques.
This single-arm, non-randomized study is limited by
the lack of a control arm and the relatively small num-
ber of patients. The results from this trial should be
confirmed within a larger, double-blind study. In addi-
tion, studies with longer follow-up beyond 1 year will be
needed.
Conclusions
This prospective study provides evidence of the safety
and effectiveness of Xenform Matrix with respect to
restoration of normal anatomy, symptom relief, quality
of life, and sexual function over a 1-year period.
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